Observations placeholder

Dronedarone - marketed as Multaq,  it was approved by the FDA  in 2009 for the treatment of atrial fibrillation and atrial flutter A trial of the drug in heart failure was stopped as an interim analysis showed a possible increase in heart failure deaths.  In order for dronedarone to be FDA approved the manufacturer had to add a Black box warning, stating that Multaq is contraindicated in patients with heart failure.  Dronedarone has been termed a “multichannel blocker” however scientists do not know which channel(s) play a pivotal role in its mechanism of action.  “Thus dronedarone’s actions at the cellular level are controversial with most studies suggesting an inhibition in multiple inward potassium currents including rapid delayed rectifier, slow delayed rectifier and Ach-activated inward rectifier”.  It is also believed to reduce rapid Na current and Ca channels.